LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Microscopy Technique Enables More Informative Biopsies

By LabMedica International staff writers
Posted on 01 Aug 2017
Print article
Image: The expansion pathology (ExPath) technique reveals expanded breast cancer tissue with nuclei visualized in 3D (Photo courtesy of the Ludwig Institute for Cancer Research).
Image: The expansion pathology (ExPath) technique reveals expanded breast cancer tissue with nuclei visualized in 3D (Photo courtesy of the Ludwig Institute for Cancer Research).
Expansion microscopy (ExM), is a method for improving the resolution of light microscopy by physically expanding a specimen, but has not been applied to clinical tissue samples. In this ExM method a tissue sample is expanded to 100 times its original volume before imaging it.

This expansion allows scientists to see features with a conventional light microscope that ordinarily could be seen only with an expensive, high-resolution electron microscope. It also reveals additional molecular information that the electron microscope cannot provide.

Scientists at Massachusetts Institute of Technology (Cambridge, MA, USA) and their colleagues developed a clinically optimized form of ExM that supports nanoscale imaging of human tissue specimens that have been fixed with formalin, embedded in paraffin, stained with hematoxylin and eosin, and/or fresh frozen. The method, which they call expansion pathology (ExPath), converts clinical samples into an ExM-compatible state, then applies an ExM protocol with protein anchoring and mechanical homogenization steps optimized for clinical samples.

The team tested this approach on tissue samples from patients with early-stage breast lesions. One way to predict whether these lesions will become malignant is to evaluate the appearance of the cells’ nuclei. Benign lesions with atypical nuclei have about a fivefold higher probability of progressing to cancer than those with typical nuclei. However, studies have revealed significant discrepancies between the assessments of nuclear atypia performed by different pathologists, which can potentially lead to an inaccurate diagnosis and unnecessary surgery. ExPath enables ~70-nm-resolution imaging of diverse biomolecules in intact tissues using conventional diffraction-limited microscopes and standard antibody and fluorescent DNA in situ hybridization reagents.

After expanding the tissue samples, the scientists analyzed them with a machine learning algorithm that can rate the nuclei based on dozens of features, including orientation, diameter, and how much they deviate from true circularity. This algorithm was able to distinguish between lesions that were likely to become invasive and those that were not, with an accuracy of 93% on expanded samples compared to only 71% on the pre-expanded tissue. They also analyzed kidney tissue samples from patients with nephrotic syndrome and when they showed the images of the expanded tissue samples to a group of scientists that included pathologists and non-pathologists, the group was able to identify the diseased tissue with 90% accuracy overall, compared to only 65% accuracy with unexpanded tissue samples.

Edward S. Boyden, PhD, a professor of Biological Engineering and co-senior author of the study, said, “Now you can diagnose nephrotic kidney disease without needing an electron microscope, a very expensive machine. You can do it with a few chemicals and a light microscope. If you can expand a tissue by one-hundredfold in volume, all other things being equal, you’re getting 100 times the information.” The study was published on July 17, 2017, in the journal Nature Biotechnology.

Related Links:
Massachusetts Institute of Technology

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more